Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Cures Boost, Lingering Appropriations Means FDA Device Funding Still An Unknown For 2017

Executive Summary

With the president's signature of the 21st Century Cures Act, US FDA has $20m in FY 2017 to begin carrying out a multitude of reforms in the law. Meanwhile, the regular budget appropriated by Congress will remain at 2016 levels through April. But as of Dec. 14, device center director Jeff Shuren said he did not know the amounts specifically that would go to his center. And now FDA supporters wonder if the Cures dollars will be tapped to do regular agency work.

Advertisement

Related Content

Congress To Focus On Cures And MACRA Oversight, MDUFA In 2017
Senate Adopts Cures Bill By Big Margin; FDA Could Tap $20m More In 2017
Senate Poised To Vote On Cures Bill; Headed To Likely Enactment This Term
Real-World Evidence User-Fee Funding Praised At FDA Meeting
US Device User-Fee Rates Will Drop About 10.3% In Fiscal 2017

Topics

Advertisement
UsernamePublicRestriction

Register

MT104212

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel